miR-543 impairs breast cancer cell phenotypes by targeting and suppressing ubiquitin-conjugating enzyme E2T (UBE2T)

References

• Woolston C. Breast cancer. Nature. 2015;527(7578):S101.
   PubMed Web of Science ®Google Scholar
• Pearce L. Breast cancer. Nursing standard (Royal College of Nursing (Great Britain): 1987). 2016;30(51):15.
   Google Scholar
• Fahad Ullah M. Breast cancer: Current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64.
   PubMed Web of Science ®Google Scholar
• Wörmann B. Breast cancer: basics, screening, diagnostics and treatment. Medizinische Monatsschrift fur Pharmazeuten. 2017;40(2):55–64.
   PubMedGoogle Scholar
• Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, et al. Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS One. 2012;7(3):e31904.
   PubMed Web of Science ®Google Scholar
• Chen P, Xu W, Luo Y, et al. MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK/MAPK. Onco Targets Ther. 2017;10:1423–1431.
   PubMed Web of Science ®Google Scholar
• Li R, Hou S, Zou M, et al. miR-543 impairs cell proliferation, migration, and invasion in breast cancer by suppressing VCAN. Biochem Biophys Res Commun. 2021;570:191–198.
   PubMed Web of Science ®Google Scholar
• Alpi AF, Chaugule V, Walden H. Mechanism and disease association of E2-conjugating enzymes: lessons from UBE2T and UBE2L3. Biochem J. 2016;473(20):3401–3419.
   PubMed Web of Science ®Google Scholar
• Rickman KA, Lach FP, Abhyankar A, et al. Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of fanconi anemia. Cell Rep. 2015;12(1):35–41.
   PubMed Web of Science ®Google Scholar
• Lim KH, Song MH, Baek KH. Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint. Cell Mol Life Sci. 2016;73(7):1439–1455.
   PubMed Web of Science ®Google Scholar
• Machida YJ, Machida Y, Chen Y, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006;23(4):589–596.
   PubMed Web of Science ®Google Scholar
• Fuentes-Antrás J, Alcaraz-Sanabria AL, Morafraile EC, et al. Mapping of genomic vulnerabilities in the post-translational ubiquitination, SUMOylation and neddylation machinery in breast cancer. Cancers (Basel). 2021;13:4.
   Web of Science ®Google Scholar
• Ueki T, Park JH, Nishidate T, et al. Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 2009;69(22):8752–8760.
   PubMed Web of Science ®Google Scholar
• Perez-Peña J, Corrales-Sánchez V, Amir E, et al. Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Sci Rep. 2017;7(1):17530.
   PubMed Web of Science ®Google Scholar
• Liu LP, Yang M, Peng QZ, et al. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. Biochem Biophys Res Commun. 2017;493(1):20–27.
   PubMed Web of Science ®Google Scholar
• Guo YJ, Pan WW, Liu SB, et al. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997–2007.
   PubMed Web of Science ®Google Scholar
• Yu Y, Luo W, Yang ZJ, et al. miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial-mesenchymal transition. Mol Cancer. 2018;17(1):70.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Wang YL, Liang RH, Wang CY, et al. MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene. Clin Transl Oncol. 2021. doi:10.1007/s12094-021-02672-z
   Web of Science ®Google Scholar
• Xu Y, Wang J, Wang J. Long noncoding RNA XIST promotes proliferation and invasion by targeting miR-141 in papillary thyroid carcinoma. Onco Targets Ther. 2018;11:5035–5043.
   PubMed Web of Science ®Google Scholar
• Liu A, Liu L, Lu H. LncRNA XIST facilitates proliferation and epithelial-mesenchymal transition of colorectal cancer cells through targeting miR-486-5p and promoting neuropilin-2. J Cell Physiol. 2019;234(8):13747–13761.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Z, Ren X, et al. Hsa-miR-330-5p Aggravates Thyroid Carcinoma via Targeting FOXE1. J Oncol. 2021;2021:1070365.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ito S, Hanafusa H, et al. Uncovering direct targets of MiR-19a involved in lung cancer progression. PLoS One. 2015;10(9):e0137887.
   PubMed Web of Science ®Google Scholar
• Ji W, Mu Q, Liu XY, et al. ZNF281-miR-543 feedback loop regulates transforming growth factor-β-induced breast cancer metastasis. Mol Ther Nucleic Acids. 2020;21:98–107.
   PubMedGoogle Scholar
• Wang H, Huang Y, Yang Y. LncRNA PVT1 regulates TRPS1 expression in breast cancer by sponging miR-543. Cancer Manag Res. 2020;12:7993–8004.
   PubMed Web of Science ®Google Scholar
• Khan AQ, Ahmed EI, Elareer NR, et al. Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells. 2019;8:8.
   Web of Science ®Google Scholar
• Kabekkodu SP, Shukla V, Varghese VK, et al. Clustered miRNAs and their role in biological functions and diseases. Biol Rev Camb Philos Soc. 2018;93(4):1955–1986.
   PubMed Web of Science ®Google Scholar
• Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234(8):12369–12384.
   PubMed Web of Science ®Google Scholar
• Babaei K, Shams S, Keymoradzadeh A, et al. An insight of microRNAs performance in carcinogenesis and tumorigenesis; an overview of cancer therapy. Life Sci. 2020;240:117077.
   PubMed Web of Science ®Google Scholar
• Bing L, Hong C, Li-Xin S, et al. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression. Arch Gynecol Obstet. 2014;290(3):533–541.
   PubMed Web of Science ®Google Scholar
• Ji T, Zhang X, Li W. MicroRNA‑543 inhibits proliferation, invasion and induces apoptosis of glioblastoma cells by directly targeting ADAM9. Mol Med Rep. 2017;16(5):6419–6427.
   PubMed Web of Science ®Google Scholar
• Pagliarini R, Shao W, Sellers WR. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 2015;16(3):280–296.
   PubMed Web of Science ®Google Scholar
• Hao J, Xu A, Xie X, et al. Elevated expression of UBE2T in lung cancer tumors and cell lines. Tumour Biol. 2008;29(3):195–203.
   PubMedGoogle Scholar
• Hao P, Kang B, Li Y, et al. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma. Mol Med Rep. 2019;20(2):1212–1220.
   PubMed Web of Science ®Google Scholar